Research Article

Heart Failure with preserved Ejection Fraction (HFpEF); A Mexican cohort from Mexican Institute of Social Security (IMSS)

Lizette Arizmendi-Ocampo, Martin Rosas Peralta*, Daniela Salinas Morales, Alejandro Chanona Espinosa, Alicia Contreras Rodriguez, Erick Ramirez Arias, Carlos Riera kinkel, Guadalupe Castro Martínez and Jose Antonio Magana-Serrano

Published: 01/28/2019 | Volume 3 - Issue 1 | Pages: 001-008

Abstract

Background: Several epidemiologic studies indicate that up to 50% of patients with heart failure have a preserved ejection fraction, and this proportion has increased over time. The knowledge of its severity and associated comorbidity is determining factor to develop adequate strategies for its treatment and prevention. This study was focus on the creation of a cohort and follow-up of Mexican population and to analyze its severity as well as its interaction with the comorbidity of other cardiovascular risk factors.

Methods: We included patients from different sites of Mexico City than were sent to the Cardiology hospital of the National Medical Center in Mexico City for the realization of an echocardiogram as part of their assessment by the presence of dyspnea, edema, or suspicion of hypertensive heart disease. Complete medical history, physical examination and laboratory studies including Brain Natriuretic Peptide (BNP) serum levels were performed. Diagnosis of diastolic dysfunction was based on symptoms and echocardiographic data including time of deceleration, size of left atrium, e´ septal and e´ lateral, as well as E wave, A wave and its ratio E/A. All patients had left ventricle ejection fraction > 45%.

Results: We included 168 patients with HFpEF. The most common risk factor was hypertension (89.2%), followed by overweight and obesity (> 78.5%), dyslipidemia (82.1%) and diabetes (42.8%). Women were dominant, 108 (64.3%); the mean age was 63 years old. When we classify by severity of diastolic dysfunction, we found that 41.1% were grade I, 57.1% were grade II and only 1.8% were grade III. The risk factors most strongly associated with the severity of diastolic dysfunction were hypertension, obesity and dyslipidemia. We found BNP levels highly variables, but the levels were higher detected as the ejection fraction was approaching to 45%. At one year of follow up mortality was not reported.

Conclusion: HFpEF is a frequent entity in patients with cardiovascular risk factors in Mexico. The most common risk factor was hypertension. The combination of hypertension, overweight and dyslipidemia predicted the severity of diastolic dysfunction. We recommend that all Mexican patient with hypertension and overweight or obesity should be submitted as a part of its medical evaluation to an echocardiogram study in order to detect diastolic dysfunction even though the signs or symptoms are or not evident.

Read Full Article HTMLDOI: 10.29328/journal.ach.1001014Cite this Article

References

  1. Redfield MM. Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2016; 375: 1868-1877. Ref.: https://goo.gl/15NsQA
  2. Verma A, Solomon SD. Diastolic dysfunction as a link between hypertension and heart failure. Med Clin North Am. 2009; 93: 647–664. Ref.: https://goo.gl/VMPuz6
  3. Gladden JD, Linke WA, Redfield MM. Heart failure with preserved ejection fraction. Pflugers Arch. 2014; 466: 1037-1053. Ref.: https://goo.gl/p8Z9Bd
  4. Campbell RT, Jhund PS, Castagno D, Hawkins NM, Petrie MC, et al. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? J Am Coll Cardiol. 2012; 60: 2349-2356. Ref.: https://goo.gl/uqKLRy
  5. Wan SH, Vogel MW, Chen HH. Pre-clinical diastolic dysfunction. J Am Coll Cardiol. 2014; 63: 407-416. Ref.: https://goo.gl/9jiHrd
  6. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194–202. Ref.: https://goo.gl/rydHDx
  7. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42: 1206–1252. Ref.: https://goo.gl/xMHwb5
  8. Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, et al. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation. 2016; 134: 73–90. Ref.: https://goo.gl/P1Weyv
  9. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006; 355: 251–259. Ref.: https://goo.gl/1NRJv7
  10. Nagueh SF. Classification of Left Ventricular Diastolic Dysfunction and Heart Failure Diagnosis and Prognosis. J Soc Am Echo. 2018; 31: 1209-1211. Ref.: https://goo.gl/qrytM8
  11. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF III, Dokainish H, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016; 29: 277-314. Ref.: https://goo.gl/XKNctv
  12. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation. 2002; 105: 1503-1508. Ref.: https://goo.gl/55jYXc
  13. Morgan JP. Abnormal intracellular modulation of calcium as a major cause of cardiac contractile dysfunction. N Engl J Med. 1991; 325: 625-632. Ref.: https://goo.gl/QACwLk
  14. Rosas-Peralta M, Borrayo-Sánchez G, Ramírez-Arias E, Jiménez-Genchi GM, Hernández-González MA, et al. Cardiovascular Risk Reduction: Past Present and Future in Mexico. Ann Clin Hypertens. 2018; 2: 038-047. Ref.: https://goo.gl/BGCk7V
  15. Chan MM, Lam CS. How do patients with heart failure with preserved ejection fraction die? Eur J Heart Fail. 2013; 15: 604-613. Ref.: https://goo.gl/sL9itT
  16. Lee DS, Gona P, Albano I, Larson MG, Benjamin EJ, et al. A systematic assessment of causes of death after heart failure onset in the community: impact of age at death, time period, and left ventricular systolic dysfunction. Circ Heart Fail. 2011; 4: 36-43. Ref.: https://goo.gl/C1RHx8
  17. Nadruz W, Shah AM, Solomon SD. Diastolic Dysfunction and Hypertension. Med Clin N Am. 2017; 101: 7–17. Ref.: https://goo.gl/sd3RX3
  18. Wan SH, Vogel MW, Chen HH. Preclinical Diastolic Dysfunction. J Am Coll Cardiol. 2014; 11; 63: 407–416. Ref.: https://goo.gl/uxU6mi
  19. Mosterd A, Hoes AW, de Bruyne MC, Deckers JW, Linker DT, et al. Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. Eur Heart J. 1999; 20: 447–455. Ref.: https://goo.gl/fq5Lp6
  20. Brouwers FP, de Boer RA, van der Harst P, Voors AA, Gansevoort RT, et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J 2013; 34: 1424–1431. Ref.: https://goo.gl/JxtcNa
  21. Tsutsui H, Tsuchihashi M, Takeshita A. Mortality and readmission of hospitalized patients with congestive heart failure and preserved versus depressed systolic function. Am J Cardiol. 2001; 88: 530–533. Ref.:
  22. Lam CS, Carson PE, Anand IS, Rector TS, Kuskowski M, et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: The Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2012; 5: 571–578. Ref.: https://goo.gl/g8dBnm
  23. Kälsch H, Lehmann N, Möhlenkamp S, Neumann T, Slomiany U, et al. Association of coronary artery calcium and congestive heart failure in the general population: Results of the Heinz Nixdorf Recall study. Clin Res Cardiol. 2010; 99: 175–182. Ref.: https://goo.gl/H4th8M